Cover Image
市場調查報告書

肥胖手術設備:醫療設備的開發平台評估

Bariatric Surgery Devices - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 408137
出版日期 內容資訊 英文 163 Pages
訂單完成後即時交付
價格
Back to Top
肥胖手術設備:醫療設備的開發平台評估 Bariatric Surgery Devices - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年09月08日 內容資訊: 英文 163 Pages
簡介

本報告提供全球肥胖手術設備的市場上的主要開發中產品 (醫療設備) 及其臨床實驗的進展調查,再彙整產品特性比較分析 (臨床實驗的各進展階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (資本交易·產業聯盟等) 等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 肥胖手術設備概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各市場區隔
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 肥胖手術設備:各企業現在臨床實驗中的開發中產品

  • 肥胖手術設備的企業:各臨床實驗階段的開發中產品
  • 肥胖手術設備:各臨床實驗階段的開發中產品

第5章 肥胖手術設備的企業·產品概要

  • 3DT Holdings, LLC
    • 開發中產品及進行中的臨床實驗概要
  • Allurion Technologies, Inc.
  • Applied Medical Resources Corporation
  • BAROnova, Inc.
  • BFKW, LLC
  • Boston Scientific Corp
  • C. R. Bard Inc
  • Columbia University
  • Crospon Ltd
  • EndoRetics Inc.
  • EndoVx Inc
  • Gelesis Inc
  • GI Dynamics Inc
  • Hebrew University of Jerusalem
  • Innovia LLC
  • John Hopkins University
  • Lotus, Ltd.
  • Mayo Clinic US
  • Medi-Globe GmbH
  • MetaModix, Inc
  • Mmtc, Inc.
  • National University of Singapore
  • Obalon Therapeutics Inc
  • Onciomed, Inc.
  • Precision Medical Devices, Inc.
  • Satiety Inc
  • Sensate LLC
  • Silhouette Medical, Inc.
  • SLIMEDICS LTD
  • FGIA, Inc
  • Standard Bariatrics, Inc.
  • Surefire Medical Inc
  • SynerZ Medical, Inc.
  • TransEnterix, Inc.
  • Tulip Medical Ltd.
  • LifeSciences LLC
  • University of Florida
  • University of Miami
  • ValenTx, Inc.
  • Vancive Medical Technologies
  • Vibrynt, Inc.

第6章 肥胖手術設備市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0435EPD

GlobalData's Medical Devices sector report, "Bariatric Surgery Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Bariatric Surgery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bariatric Surgery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Bariatric Surgery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bariatric Surgery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bariatric Surgery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 10

2 Introduction 11

  • 2.1 Bariatric Surgery Devices Overview 11

3 Products under Development 12

  • 3.1 Bariatric Surgery Devices - Pipeline Products by Stage of Development 12
  • 3.2 Bariatric Surgery Devices - Pipeline Products by Segment 13
  • 3.3 Bariatric Surgery Devices - Pipeline Products by Territory 14
  • 3.4 Bariatric Surgery Devices - Pipeline Products by Regulatory Path 15
  • 3.5 Bariatric Surgery Devices - Pipeline Products by Estimated Approval Date 16
  • 3.6 Bariatric Surgery Devices - Ongoing Clinical Trials 17

4 Bariatric Surgery Devices - Pipeline Products under Development by Companies 18

  • 4.1 Bariatric Surgery Devices Companies - Pipeline Products by Stage of Development 18
  • 4.2 Bariatric Surgery Devices - Pipeline Products by Stage of Development 20

5 Bariatric Surgery Devices Companies and Product Overview 22

  • 5.1 3DT Holdings, LLC Company Overview 22
    • 5.1.1 3DT Holdings, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.2 Allurion Technologies, Inc. Company Overview 23
    • 5.2.1 Allurion Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.3 Apollo Endosurgery Inc Company Overview 26
    • 5.3.1 Apollo Endosurgery Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.4 Applied Medical Resources Corporation Company Overview 27
    • 5.4.1 Applied Medical Resources Corporation Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.5 BAROnova, Inc. Company Overview 28
    • 5.5.1 BAROnova, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.6 BFKW, LLC Company Overview 31
    • 5.6.1 BFKW, LLC Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.7 Boston Scientific Corp Company Overview 32
    • 5.7.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.8 C. R. Bard Inc Company Overview 33
    • 5.8.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.9 Columbia University Company Overview 34
    • 5.9.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.10 Crospon Ltd Company Overview 35
    • 5.10.1 Crospon Ltd Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.11 EndoRetics Inc. Company Overview 36
    • 5.11.1 EndoRetics Inc. Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.12 EndoVx Inc Company Overview 37
    • 5.12.1 EndoVx Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.13 EnteroMedics Inc Company Overview 38
    • 5.13.1 EnteroMedics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.14 Gelesis Inc Company Overview 41
    • 5.14.1 Gelesis Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.15 GI Dynamics Inc Company Overview 47
    • 5.15.1 GI Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.16 Hebrew University of Jerusalem Company Overview 51
    • 5.16.1 Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.17 Innovia LLC Company Overview 52
    • 5.17.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.18 John Hopkins University Company Overview 54
    • 5.18.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.19 Mayo Clinic US Company Overview 55
    • 5.19.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.20 Medi-Globe GmbH Company Overview 56
    • 5.20.1 Medi-Globe GmbH Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.21 MetaModix, Inc Company Overview 57
    • 5.21.1 MetaModix, Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.22 Mmtc, Inc. Company Overview 59
    • 5.22.1 Mmtc, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.23 National University of Singapore Company Overview 60
    • 5.23.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.24 Precision Medical Devices, Inc. Company Overview 61
    • 5.24.1 Precision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.25 Satiety Inc Company Overview 62
    • 5.25.1 Satiety Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.26 Sensate LLC Company Overview 65
    • 5.26.1 Sensate LLC Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.27 Silhouette Medical, Inc. Company Overview 66
    • 5.27.1 Silhouette Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.28 SLIMEDICS LTD Company Overview 67
    • 5.28.1 SLIMEDICS LTD Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.29 Spatz FGIA, Inc Company Overview 68
    • 5.29.1 Spatz FGIA, Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.30 Standard Bariatrics, Inc. Company Overview 69
    • 5.30.1 Standard Bariatrics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.31 Surefire Medical Inc Company Overview 70
    • 5.31.1 Surefire Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.32 SynerZ Medical, Inc. Company Overview 71
    • 5.32.1 SynerZ Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
  • 5.33 The Sheikh Zayed Institute for Pediatric Surgical Innovation Company Overview 72
    • 5.33.1 The Sheikh Zayed Institute for Pediatric Surgical Innovation Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.34 TransEnterix, Inc. Company Overview 73
    • 5.34.1 TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.35 Tulip Medical Ltd. Company Overview 74
    • 5.35.1 Tulip Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 74
  • 5.36 UAS LifeSciences LLC Company Overview 75
    • 5.36.1 UAS LifeSciences LLC Pipeline Products & Ongoing Clinical Trials Overview 75
  • 5.37 University of Florida Company Overview 76
    • 5.37.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 76
  • 5.38 University of Miami Company Overview 77
    • 5.38.1 University of Miami Pipeline Products & Ongoing Clinical Trials Overview 77
  • 5.39 ValenTx, Inc. Company Overview 78
    • 5.39.1 ValenTx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
  • 5.40 Vancive Medical Technologies Company Overview 81
    • 5.40.1 Vancive Medical Technologies Pipeline Products & Ongoing Clinical Trials Overview 81
  • 5.41 Vibrynt, Inc. Company Overview 82
    • 5.41.1 Vibrynt, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82

6 Bariatric Surgery Devices- Recent Developments 83

  • 6.1 Aug 31, 2017: Apollo Endosurgery Announces 20-year LAP-BAND Outcomes Data Presented at 22nd IFSO World Congress in London 83
  • 6.2 Aug 30, 2017: Apollo Endosurgery Announces CE Mark Approval for the ORBERA365 Managed Weight Loss System, Expanding the Indwell Period from 6 Months to 12 Months with the Gastric Balloon Category Leader 84
  • 6.3 Aug 23, 2017: GI Dynamics Appoints Juliet Thompson to Company's Board of Directors 84
  • 6.4 Aug 23, 2017: Senior Novartis Executive Joins Proteus Digital Health as Chief Financial Officer 85
  • 6.5 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 86
  • 6.6 Aug 21, 2017: EnteroMedics Announces First Veterans Choice Program vBloc Implant at MedStar Health in Maryland 88
  • 6.7 Aug 16, 2017: EnteroMedics Announces Presentations Highlighting vBloc and Gastric Vest at IFSO Annual Conference 89
  • 6.8 Aug 13, 2017: GI Dynamics Welcomes New Members to its Scientific Advisory Board 90
  • 6.9 Aug 10, 2017: Apollo Endosurgery Provides Update And Clarity To FDA Letter To Health Care Providers Related To Potential Risks Of Intragastric Balloons 91
  • 6.10 Aug 08, 2017: EnteroMedics Announces Second Quarter 2017 Financial Results 92
  • 6.11 Aug 02, 2017: Obalon Announces Second Quarter 2017 Financial Results 93
  • 6.12 Aug 01, 2017: Apollo Endosurgery Reports Second Quarter 2017 Results 93
  • 6.13 Jul 31, 2017: EnteroMedics Receives Approval for Gastric Vest System Clinical Study in Spain 95
  • 6.14 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 95
  • 6.15 Jul 12, 2017: Gelesis Announces Last Patient Out in the Pivotal Gelesis100 Weight-Loss Study 97
  • 6.16 Jul 12, 2017: Gelesis Announces Data on Gelesis200 98
  • 6.17 Jul 12, 2017: Apollo Endosurgery Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017 98
  • 6.18 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 99
  • 6.19 Jun 21, 2017: Aspire Bariatrics Announces AspireAssist Receives Australian TGA Approval and First Commercial Cases Performed in Australia 101
  • 6.20 Jun 21, 2017: EnteroMedics Announces vBloc Therapy to be Presented by Keynote Speaker at Major International Obesity Conference 101
  • 6.21 Jun 19, 2017: GI Dynamics Announces Additional Members to Its Scientific Advisory Board 102
  • 6.22 Jun 11, 2017: First Data Derived from ABCD Worldwide EndoBarrier Registry Presented at ADA Shows Sustained Metabolic Improvements in Patients with Obesity and Type 2 Diabetes at Six Months Post-explant 103
  • 6.23 Jun 02, 2017: GI Dynamics Announces Change to Board of Directors 104
  • 6.24 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 104
  • 6.25 May 19, 2017: Vizient Submits Comments to the FDA about Biosimilar Interchangeability, Looks Forward to Working toward Lowering Drug Costs 107
  • 6.26 May 16, 2017: EnteroMedics Announces First Quarter 2017 Financial Results 107
  • 6.27 May 11, 2017: Obalon Receives Regulatory Approvals to Commercialize in Select Middle East Markets 108
  • 6.28 May 10, 2017: Obalon Announces First Quarter 2017 Financial Results 108
  • 6.29 May 08, 2017: GI Dynamics Announces Scientific Advisory Board Members to Further Development of EndoBarrier 108
  • 6.30 May 04, 2017: Apollo Endosurgery Reports First Quarter 2017 Results 109
  • 6.31 May 03, 2017: GI Dynamics Announces EndoBarrier Data to be Presented at Digestive Disease Week 111
  • 6.32 May 02, 2017: Apollo Endosurgery To Present Data on ORBERA Intragastric Balloon System at Digestive Disease Week 2017 Conference 112
  • 6.33 Apr 28, 2017: Obalon Balloon System to be Included in Two Presentations at the Aesthetic Meeting 2017 112
  • 6.34 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 113
  • 6.35 Apr 25, 2017: BarioSurg Showcasing Its Next Generation Obesity Technology, the Gastric Vest System at the VII Medical Congress Angeles Group 114
  • 6.36 Apr 23, 2017: Bard Announces First Quarter Results 114
  • 6.37 Apr 03, 2017: Michigan Physician Successfully Performs First AspireAssist Non-Surgical Weight Loss Procedures In The State 115
  • 6.38 Mar 28, 2017: Genesis Automation Awarded Group Purchasing Contract with Vizient To Provide Integrated Supply Chain Management Technology 116
  • 6.39 Mar 15, 2017: David Moatazedi Joins Obalon Therapeutics Board of Directors 116
  • 6.40 Mar 13, 2017: GI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier 117
  • 6.41 Mar 08, 2017: Apollo Endosurgery Reports Fourth Quarter and Full Year 2016 Results 117
  • 6.42 Mar 07, 2017: GI Dynamics Announces New Scientific Advisory Board and Board's First Two Members 119
  • 6.43 Mar 07, 2017: EnteroMedics Reports Fourth Quarter 2016 Financial Results 120
  • 6.44 Mar 06, 2017: TransEnterix Reports Operating Results for the Fourth Quarter and Full Year 2016 121
  • 6.45 Mar 01, 2017: ZELTIQ Announces Fourth Quarter and Full Year 2016 Financial Results 122
  • 6.46 Feb 23, 2017: Obalon Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results 124
  • 6.47 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 125
  • 6.48 Feb 09, 2017: EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity 127
  • 6.49 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 128
  • 6.50 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 129
  • 6.51 Jan 31, 2017: GI Dynamics: Quarterly Report - Quarter Ended 31 December 2016 130
  • 6.52 Jan 30, 2017: New Jersey Bariatric Center Performs First Obalon Gastric Balloon Procedure for Weight Loss in NJ 130
  • 6.53 Jan 26, 2017: Bard Announces Fourth Quarter Results 131
  • 6.54 Jan 25, 2017: BAROnova Announces Completion of ENDObesity II Pivotal Clinical Trial Enrollment 132
  • 6.55 Jan 24, 2017: Mayo Clinic Selects Vizient as Its Performance Improvement Partner 132
  • 6.56 Jan 18, 2017: FDA Approves Obalon Balloon System 133
  • 6.57 Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer 133
  • 6.58 Jan 17, 2017: Jonah Shacknai Joins Obalon Therapeutics Board of Directors 134
  • 6.59 Jan 13, 2017: Obalon Announces Initial Commercial Patient Placements of the First and Only Swallowable, FDA-Approved Balloon System for Weight Loss 134
  • 6.60 Jan 11, 2017: GI Dynamics Provides 2017 Business Outlook and 2016 Review 135
  • 6.61 Jan 09, 2017: ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2016 Revenue and Provides 2017 Guidance 136
  • 6.62 Jan 09, 2017: ZELTIQ Aesthetics Announces Commercial Leadership Transition 138
  • 6.63 Jan 05, 2017: Aspire Bariatrics Announces Two-Year Observational Study Results Published in BMC Obesity for AspireAssist 138
  • 6.64 Jan 05, 2017: GI Dynamics Appoints Oern R. Stuge, MD, Amid Change to Company's Board of Directors 139
  • 6.65 Dec 14, 2016: BMI of Texas Selected as Exclusive Provider of Obalon System 140
  • 6.66 Dec 06, 2016: AspireAssist Pivotal Trial Results Published in the American Journal of Gastroenterology 140
  • 6.67 Dec 06, 2016: Dedicated to Innovation: Next-Generation Vanquish ME Device from BTL Aesthetics Reduces 53% More Fat Than its Predecessor 141
  • 6.68 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 142
  • 6.69 Nov 22, 2016: EnteroMedics Provides Commercialization and Corporate Update 145
  • 6.70 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 146
  • 6.71 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 147
  • 6.72 Nov 11, 2016: Obalon Therapeutics Announces Third Quarter Financial Results 147
  • 6.73 Nov 09, 2016: TransEnterix Reports Operating Results for the Third Quarter 2016 148
  • 6.74 Nov 09, 2016: ZELTIQ Announces Third Quarter 2016 Financial Results 149
  • 6.75 Nov 04, 2016: ReShape Medical Unveils US Commercial Data Demonstrating Increased Weight Loss with ReShape Dual Balloon 150
  • 6.76 Nov 04, 2016: Obalon Announces Data Presentation at the Annual Meeting of the American Society for Metabolic and Bariatric Surgery 151
  • 6.77 Nov 02, 2016: Apollo Endosurgery Announces Successful Completion of LAP-BAND FDA Post-Approval Study 152
  • 6.78 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 153
  • 6.79 Oct 25, 2016: Bard Announces Third Quarter Results 154
  • 6.80 Oct 17, 2016: Freudenberg Medical Recognized at Medical Device Design Excellence Awards 155
  • 6.81 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 155
  • 6.82 Sep 28, 2016: New York Bariatric Group is the First Medical Practice in America Since FDA Approval to Perform Non Surgical Weight Loss Solution - AspireAssist 156
  • 6.83 Sep 28, 2016: Vizient Launches Ediom, a Cognitive Computing and Data Science Company 156
  • 6.84 Sep 27, 2016: EnteroMedics Announces Appointment of Dan Gladney as Chairman of the Board of Directors 157
  • 6.85 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 157
  • 6.86 Sep 12, 2016: Obalon Announces FDA Approval Of Obalon Balloon System 158

7 Appendix 160

  • 7.1 Methodology 160
  • 7.2 About GlobalData 163
  • 7.3 Contact Us 163
  • 7.4 Disclaimer 163

List of Tables

1.1 List of Tables

  • Table 1: Bariatric Surgery Devices - Pipeline Products by Stage of Development 12
  • Table 2: Bariatric Surgery Devices - Pipeline Products by Segment 13
  • Table 3: Bariatric Surgery Devices - Pipeline Products by Territory 14
  • Table 4: Bariatric Surgery Devices - Pipeline Products by Regulatory Path 15
  • Table 5: Bariatric Surgery Devices - Pipeline Products by Estimated Approval Date 16
  • Table 6: Bariatric Surgery Devices - Ongoing Clinical Trials 17
  • Table 7: Bariatric Surgery Devices Companies - Pipeline Products by Stage of Development 18
  • Table 8: Bariatric Surgery Devices - Pipeline Products by Stage of Development 20
  • Table 9: 3DT Holdings, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 10: Gastric Sleeve Magnetic Implant - Product Status 22
  • Table 11: Gastric Sleeve Magnetic Implant - Product Description 22
  • Table 12: Allurion Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 13: Elipse Balloon - Product Status 23
  • Table 14: Elipse Balloon - Product Description 23
  • Table 15: Allurion Technologies, Inc. - Ongoing Clinical Trials Overview 24
  • Table 16: Elipse Balloon - A Randomized, Multi-center, Phased, Pivotal Safety and Efficacy Study Comparing the Elipse Gastric Balloon System Versus Sham for the Treatment of Obese Adults 25
  • Table 17: Elipse Balloon - Pilot Trial of the Elipse Intragastric Balloon System for the Treatment of Overweight and Obese Individuals 25
  • Table 18: Apollo Endosurgery Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 19: ORBERA365 Managed Weight Loss System - Product Status 26
  • Table 20: ORBERA365 Managed Weight Loss System - Product Description 26
  • Table 21: Applied Medical Resources Corporation Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 22: Next Generation Bariatric Surgical Device - Product Status 27
  • Table 23: Next Generation Bariatric Surgical Device - Product Description 27
  • Table 24: BAROnova, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 25: TransPyloric Shuttle Device - Product Status 28
  • Table 26: TransPyloric Shuttle Device - Product Description 28
  • Table 27: BAROnova, Inc. - Ongoing Clinical Trials Overview 29
  • Table 28: TransPyloric Shuttle Device - Endoscopic Treatment for Weight Reduction in Patients with Obesity Using the TransPyloric Shuttle System: A Multicenter, Prospective, Randomized, Double-blind, Sham-controlled, Parallel-design Study 30
  • Table 29: BFKW, LLC Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 30: Full Sense - Product Status 31
  • Table 31: Full Sense - Product Description 31
  • Table 32: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 33: TERIS - Product Status 32
  • Table 34: TERIS - Product Description 32
  • Table 35: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 36: Restore Suturing System - Product Status 33
  • Table 37: Restore Suturing System - Product Description 33
  • Table 38: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 39: Gastric Bypass Shunt - Product Status 34
  • Table 40: Gastric Bypass Shunt - Product Description 34
  • Table 41: Crospon Ltd Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 42: BaroFLIP System - Product Status 35
  • Table 43: BaroFLIP System - Product Description 35
  • Table 44: EndoRetics Inc. Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 45: Endoretics Device - Product Status 36
  • Table 46: Endoretics Device - Product Description 36
  • Table 47: EndoVx Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 48: EndoVx Device - Product Status 37
  • Table 49: EndoVx Device - Product Description 37
  • Table 50: EnteroMedics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 51: Gastric Vest System - Product Status 38
  • Table 52: Gastric Vest System - Product Description 38
  • Table 53: EnteroMedics Inc - Ongoing Clinical Trials Overview 39
  • Table 54: Gastric Vest System - Safety and Performance Study for the Gastric Vest System: CE Mark Study 40
  • Table 55: Gelesis Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 56: Gelesis100 - Product Status 41
  • Table 57: Gelesis100 - Product Description 41
  • Table 58: Gelesis100 Pediatric And Obese Overweight - Product Status 42
  • Table 59: Gelesis100 Pediatric And Obese Overweight - Product Description 42
  • Table 60: Gelesis100 Prediabetic And Diabetic Overweight - Product Status 42
  • Table 61: Gelesis100 Prediabetic And Diabetic Overweight - Product Description 43
  • Table 62: Gelesis200 - Product Status 43
  • Table 63: Gelesis200 - Product Description 43
  • Table 64: Gelesis Inc - Ongoing Clinical Trials Overview 44
  • Table 65: Gelesis100 - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes 45
  • Table 66: Gelesis100 - An Open-label Study Assessing the Effect of Gelesis100 on Weight Loss and Weight Maintenance in Overweight and Obese Subjects Who Completed the GLOW Study (G-04) 45
  • Table 67: Gelesis200 - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects with Prediabetes and Met Forming-treated Type 2 Diabetes 46
  • Table 68: Gelesis200 - A Randomized, Open-label, Crossover Study Assessing the Effects of Gelesis200 on Glucose and Insulin Following a Single Administration of Gelesis200 in Healthy Subjects 46
  • Table 69: GI Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 70: EndoBarrier Flow Restrictor - Product Status 47
  • Table 71: EndoBarrier Flow Restrictor - Product Description 48
  • Table 72: EndoBarrier Liner With EndoBarrier Restrictor - Product Status 48
  • Table 73: EndoBarrier Liner With EndoBarrier Restrictor - Product Description 48
  • Table 74: GI Dynamics Inc - Ongoing Clinical Trials Overview 49
  • Table 75: EndoBarrier Liner With EndoBarrier Restrictor - Endoscopic Treatment of Obesity with a Duodenal-jejunal Bypass Sleeve: Does Impairment of Fat Absorption Explain Weight Loss 50
  • Table 76: EndoBarrier Liner With EndoBarrier Restrictor - Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) 50
  • Table 77: Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 78: MetaboShield - Product Status 51
  • Table 79: MetaboShield - Product Description 51
  • Table 80: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 81: Gastric Balloon - Product Status 52
  • Table 82: Gastric Balloon - Product Description 52
  • Table 83: Gastric Sleeve - Product Status 53
  • Table 84: Gastric Sleeve - Product Description 53
  • Table 85: Laparoscopic Band - Product Status 53
  • Table 86: Laparoscopic Band - Product Description 53
  • Table 87: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 88: Image-guided Bariatric Arterial Embolization Device - Product Status 54
  • Table 89: Image-guided Bariatric Arterial Embolization Device - Product Description 54
  • Table 90: Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 91: Endoscopic Therapy Device - Obesity - Product Status 55
  • Table 92: Endoscopic Therapy Device - Obesity - Product Description 55
  • Table 93: Medi-Globe GmbH Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 94: Medi-Globe Gastric Balloon - Product Status 56
  • Table 95: Medi-Globe Gastric Balloon - Product Description 56
  • Table 96: MetaModix, Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 97: Endosleeve - Product Status 57
  • Table 98: Endosleeve - Product Description 57
  • Table 99: Second Generation Liner Device - Product Status 58
  • Table 100: Second Generation Liner Device - Product Description 58
  • Table 101: Mmtc, Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 102: Wearable BAT Monitor - Product Status 59
  • Table 103: Wearable BAT Monitor - Product Description 59
  • Table 104: National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 105: Weight Management Device - Product Status 60
  • Table 106: Weight Management Device - Product Description 60
  • Table 107: Precision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 108: Flow Control Device - Obesity - Product Status 61
  • Table 109: Flow Control Device - Obesity - Product Description 61
  • Table 110: Satiety Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 111: TOGA System - Product Status 62
  • Table 112: TOGA System - Product Description 62
  • Table 113: Satiety Inc - Ongoing Clinical Trials Overview 63
  • Table 114: TOGA System - Endoscopic Bariatric Stapling Pilot Study 64
  • Table 115: Sensate LLC Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 116: Sensate Anchored Gastric Device - Product Status 65
  • Table 117: Sensate Anchored Gastric Device - Product Description 65
  • Table 118: Silhouette Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 119: nObese Device - Product Status 66
  • Table 120: nObese Device - Product Description 66
  • Table 121: SLIMEDICS LTD Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 122: Intra Gastric Implant - Product Status 67
  • Table 123: Intra Gastric Implant - Product Description 67
  • Table 124: Spatz FGIA, Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 125: Spatz3 Adjustable Balloon System - Product Status 68
  • Table 126: Spatz3 Adjustable Balloon System - Product Description 68
  • Table 127: Standard Bariatrics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 128: Gastrectomy Stapling Guide - Product Status 69
  • Table 129: Gastrectomy Stapling Guide - Product Description 69
  • Table 130: Surefire Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 131: Surefire Infusion Catheter System - Obesity - Product Status 70
  • Table 132: Surefire Infusion Catheter System - Obesity - Product Description 70
  • Table 133: SynerZ Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 134: Aegis Device - Product Status 71
  • Table 135: Aegis Device - Product Description 71
  • Table 136: The Sheikh Zayed Institute for Pediatric Surgical Innovation Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 137: Obesity Balloon - Product Status 72
  • Table 138: Obesity Balloon - Product Description 72
  • Table 139: TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 140: Intraluminal Gastroplasty Device - Obesity - Product Status 73
  • Table 141: Intraluminal Gastroplasty Device - Obesity - Product Description 73
  • Table 142: Tulip Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 143: Tulip Capsule - Product Status 74
  • Table 144: Tulip Capsule - Product Description 74
  • Table 145: UAS LifeSciences LLC Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 146: Ingestible Gastrointestinal Sampling Device - Product Status 75
  • Table 147: Ingestible Gastrointestinal Sampling Device - Product Description 75
  • Table 148: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 149: Mutated Gene Repair System - Product Status 76
  • Table 150: Mutated Gene Repair System - Product Description 76
  • Table 151: University of Miami Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 152: EEA Anvil Placement Device - Product Status 77
  • Table 153: EEA Anvil Placement Device - Product Description 77
  • Table 154: ValenTx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 155: ValenTx Endoluminal Bypass System - Product Status 78
  • Table 156: ValenTx Endoluminal Bypass System - Product Description 78
  • Table 157: ValenTx, Inc. - Ongoing Clinical Trials Overview 79
  • Table 158: ValenTx Endoluminal Bypass System - An Open Label Trial of the Safety and Effectiveness of the ValenTx Endo Bypass System and Use of the Endoscopic Anchor Placement Device in Obese Subjects 80
  • Table 159: ValenTx Endoluminal Bypass System - Safety and Efficacy of the ValenTx EndoPass System for the Treatment of Obese Subjects: The ePass Clinical Trial 80
  • Table 160: Vancive Medical Technologies Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 161: 7-Day Body Monitor Patch - Product Status 81
  • Table 162: 7-Day Body Monitor Patch - Product Description 81
  • Table 163: Vibrynt, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 164: PREVAIL Implant System - Product Status 82
  • Table 165: PREVAIL Implant System - Product Description 82
  • Table 166: Glossary 162

List of Figures

1.2 List of Figures

  • Figure 1: Bariatric Surgery Devices - Pipeline Products by Stage of Development 12
  • Figure 2: Bariatric Surgery Devices - Pipeline Products by Segment 13
  • Figure 3: Bariatric Surgery Devices - Pipeline Products by Territory 14
  • Figure 4: Bariatric Surgery Devices - Pipeline Products by Regulatory Path 15
  • Figure 5: Bariatric Surgery Devices - Pipeline Products by Estimated Approval Date 16
  • Figure 6: Bariatric Surgery Devices - Ongoing Clinical Trials 17
Back to Top